Trial
NCT04457336
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Spruce Biosciences
Collaborators
—
Condition
Congenital Adrenal Hyperplasia
Intervention
Tildacerfont/Placebo
Why stopped
Study SPR001-203 did not meet its primary and secondary endpoints therefore Spruce Biosciences has decided to terminate the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-08